# The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE

> **NCT07185269** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 198 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** 626
- **DRUG:** 626
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07185269
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-24
- **Primary completion:** 2028-08-12
- **Final completion:** 2028-11-04
- **Target enrollment:** 198 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185269, "The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT07185269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*